BCL2 and cancer: This combination strategy is under investigation and can effectively inhibit most cancer-related anti-apoptotic BCL-2 family members, thereby expanding to heterogeneous indications and overcoming resistance to current BCL-2/BCL-XL-targeted therapies [116].